University Hospital Southampton (UHS) NHS Foundation Trust has signed a commercial collaboration agreement with Automata to develop new applications for laboratory automation technology
Automata is a London based biotech company providing robotic automation solutions to the life sciences industry. Comprising proprietary hardware, single-platform software and a world-class service, Automata partners with labs to take the hassle out of automation, empowering them to achieve more reliable results faster than ever before.
Following Automata’s successful implementation of new automated technology as part of the national COVID-19 testing programme response, they are developing their partnership with University Hospital Southampton NHS Foundation Trust (UHS) to explore future clinical use cases in other areas of laboratory medicine.
The partnership aims to optimise Automata’s expertise in lab automation at scale, drawing upon UHS as a development partner and reference site.
Martin Gossling, Head of Commercial Innovation at UHS, said: “A key legacy of delivering saliva testing as part of the national COVID-19 response has been how we can apply the automation of processes on a wider scale across the clinical sector.
“Partnering with Automata has allowed us to combine our knowledge of laboratory work and access to it, with their technological solutions that will ultimately result in more efficient processes at scale that will benefit the NHS and the patients we serve.”
Mostafa ElSayed, CEO & CoFounder Automata adds: “It’s fantastic to be partnering with the NHS to demonstrate how our technology can answer the need for exceptionally reliable solutions that enable scalability, enhance capacity, and empower over-stretched workforces. The whole team at Automata are proud to be helping our amazing NHS scientists achieve better results faster with worry-free lab automation from Automata Labs.”
Automata is a London based biotech company providing robotic automation solutions to the life sciences industry.
Life Science labs are driving human innovation, yet automation challenges are still holding them back. Their processes are limited by constrained working hours, people conducting repetitive tasks and current lab automation technologies automating only parts of the assay.
With Automata Labs, life science laboratories can increase the reliability, quality and reproducibility of their results. They can shorten turnaround times by scaling capacities, while reducing costs.
Most of all, we enable scientists to spend more time on their analyses, the bedrock for innovation.